3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Breast
1
Conditions
Breast Neoplasms
48
Neoplasm Metastasis
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hyperglycemia
3
Multiple Endocrine Neoplasia Type 1
2
Advanced Breast Cancer
2
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Pancreatic Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal, Breast
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced HER2+Breast Cancer
1
Interventions
pembrolizumab
24
Paclitaxel
11
Carboplatin
11
Trastuzumab
9
Nivolumab
7
Fulvestrant
6
palbociclib
4
olaparib
4
Taxes
4
Surveys and Questionnaires
4
Methods
4
Early Intervention, Educational
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
pertuzumab
3
lenvatinib
3
fludarabine
3
atezolizumab
3
abemaciclib
3
Tamoxifen
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Metformin
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interviews as Topic
3
Gemcitabine
3
Counseling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Alpelisib
×
Breast
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled